Detection of Dengue Virus RNA in Blood Donors from Honduras and Brazil with a Prototype Transcription-Mediated Amplification Assay.

Slides:

Advertisements

Similar presentations

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Advertisements

Vector-Borne & Water-Borne Diseases

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.

National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.

Urban Growth in Asian Cities Spread of dengue hemorrhagic fever in Asia.

GENERAL AWARENESS ON HIV/AIDS Presented by: WeHELP In Association with its MEDICAL TEAM.

Plague CDC, AFIP. Diseases of Bioterrorist Potential Learning Objectives Describe the epidemiology, mode of transmission, and presenting symptoms of disease.

Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.

Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.

To evaluate sensitivity, each of the 76 specimens (38 serum pairs) were tested using three serology tests. All testing was performed at the university.

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,

DENGUE: EPIDEMIOLOGY PART 1

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

OnSite TB/HIV Ab Rapid Test 2 in 1 test kit

Dengue Virus and Its Risk to the U.S. Blood Supply

1 Susan L. Stramer, PhD and collaborators from: American Red Cross, Gaithersburg, MD American Red Cross, Charlotte National Laboratory, Charlotte, NC American.

HIV Testing CDC power point edited by M. Myers

Laboratory Investigation

TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;

C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.

World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.

ENIVD 06/06 02:19 First international proficiency study on West Nile virus molecular detection. Matthias Niedrig, Sonja Linke Christian Drosten Hervé Zeller.

OnSite Dengue Rapid Test.

Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.

Laboratory Issues and West Nile Virus Hema Kapoor MD. SM (NRM)

DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.

E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.

ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES XVIII International AIDS Conference, July , Vienna Austria Recent Trends in estimated HIV-1.

Theresa L. Smith, MD, MPH Division of Vector-Borne Infectious Diseases Centers for Disease Control and Prevention Fort Collins, CO West Nile Virus Epidemiology.

Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.

Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

U.S. Influenza Surveillance Keiji Fukuda Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.

Qualification Panels for West Nile Virus RNA Tests Mark Manak, Ph.D. Boston Biomedica, Inc. West Bridgewater, MA SoGAT Langen, Germany July 3, 2003.

Overview of Data on Blood Donor Testing and Plan for Studies to Characterize Rates and Consequences of Transfusion Transmission of Dengue Virus Michael.

1 Blood Systems Trypanosoma cruzi and Chagas Disease Studies and Potential Strategies for Targeted Testing of Donors Blood Products Advisory Committee.

1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,

Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

West Nile Virus: Pathogenesis and Diagnostic Tools Maria Rios, PhD - Senior Staff Fellow Laboratory of Molecular Virology DETTD/OBRR/CBER/FDA WNV epidemic.

Xenotropic Murine Leukemia Virus-Related Retrovirus: CCR Assay Development.

Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.

SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.

Maternofetal transmission of human parvovirus B19 genotype 3 in Ghana, West Africa D Candotti, K Danso, A Parsyan, A Dompreh, J- P Allain National Blood.

PROPOSED CANDIDATE MATERIAL FOR A WHO PANEL FOR SEROLOGICAL REFERENCE RESULTS OF THE FEASIBILITY STUDIES WITH SERA FROM TC I REGION RESULTS OF THE FEASIBILITY.

Test 1Test 2Test 3Test 4Test 5Test 6 Sensitivity Specificity PPV NPV Performance.

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,

Recent Serologic Studies with Potential Impact on WNV Blood Screening Wayne Hogrefe, Harry Prince Focus Technologies.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

1 Update on Study to Further Define the Incidence of T. cruzi Infection in the US Blood Donor Population Susan L. Stramer, PhD American Red Cross BPAC.

RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.

Preventing Transmission of Chagas Disease in the U.S. Blood Supply: A Cost Effectiveness Analysis of Testing the Blood Bank Donations Danielle Doughman.

Proposed candidate materials and results of the feasibility studies for a WHO serological reference panel T.cruzi type II Márcia Otani Fundação Pró-Sangue.

Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.

Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.

Abbott HCV core Ag and HCV RNA Comparison Study

Public Health Response to Zika Virus in California

Dengue Fever Amy Whitesell March 22, 2016.

European Centre for Disease Prevention and Control

Dengue Virus Infections Investigation Guideline

Update on CBER HIV-1 Subtype panel

HEPATITIS C BY MBBSPPT.COM

Presentation transcript:

Detection of Dengue Virus RNA in Blood Donors from Honduras and Brazil with a Prototype Transcription-Mediated Amplification Assay

Dengue Over 2.5 billion people live in risk areas for dengue infection WHO estimates that in 2004 there were million cases of DF, 500,000 cases of dengue hemorrhagic shock syndrome (DHS) and 20,000 consequent deaths Epidemic is expanding due to global warming, expanding vectors and trafficking of subtypes Dengue the most important arboviral disease of humans

Expanding global epidemic of Dengue

Number of dengue fever cases reported per month, Brazil. A) 1986–1993, B) 1994–2003. Dark bars represent January.

Curvas epidémicas del 2002, 2003,2004 Y 2005* Casos Sospechosos de Dengue Clásico Honduras, *Semana 41 * AÑO EPIDÉMICO 1995 EXCLUÍDO 2003 (16,559 casos) FUENTE: Telegrama Epidemiológico (32,269 casos) 2004 (19,971 casos) 2005 (16,037 casos)*

Analytical sensitivity of the prototype dengue TMA assay DEN 1, 2, 3 and 4 diluted to 1 PFU/mL

Sources of Donor Plasma from Dengue Endemic Regions CountryHondurasBrasilAustralia RegionTequciqalpa San Pedro Sula Sao Paulo Cairin s Townsville Brisban e Cairins & Townsville Period 08/31/04- 01/24/05 09/06/04- 01/13/05 Feb Apr Total by Region Total by Country IR, 9 RR 11 confirmed 8 IR, 3 IR confirmation pending in progress

Dengue TMA Results from Honduran Blood Donors (n = 2994) Specimen ID Initial TMA Results Repeat TMA Results BSRI Genotyping CDC Genotypin g Growth in culture (CDC) Duplicate Viral Load Testing (PFU/100 uL of plasma) DV-00033Reactive Nonreactiv e DEN-1Negative <0.001 DV-00164Reactive DEN DV-00220Reactive DEN DV-00477Reactive DEN DV-00545Reactive DEN DV-00766Reactive Nonreactiv e Negative Neg DV-00802Reactive DEN-4Negative 0.25 DV-01110Reactive DEN-1 Negative0.54 DV-01328Reactive DEN-1 Negative20.00 DV-02221Reactive Nonreactiv e DEN-3Negative DV-02837Reactive DEN-2 Negative0.01 DV-02921Reactive DEN-3Negative 0.002

Planned studies of TT-Dengue Transmission study in Honduras with BSF and Gen-Probe funding Transmission study in Brazil under REDS- II funding Collaborations with Australia, Hong Kong and Singapore blood banks

Dengue Transmission Study Approach It is mandatory in Brazil to save donor serum samples for 6 months after the transfusion Phase 1: Prevalence Study –Dengue TMA on 10,000 unlinked donor samples to determine prevalence Phase 2: Transmission Study –collect recipient samples ~1 week after transfusion. –capture donor samples in routine repository. –Dengue TMA on both samples. –sequence virus to confirm linkage

Acknowledgements J Linnen, A Broulik, C Collins, DP Kolk, C Giachetti, L Mimms Gen-Probe Incorporated, San Diego, CA; E Vinelli Honduran Red Cross, Tegucigalpa, Honduras; E Sabino, Blood Center of Sao Paulo, Sao Paulo, Brazil; R Lanciotti, CDC, Fort Collins, CO; C Hyland, Australian Red Cross, Brisbane, Australia; L Tobler, MP Busch Blood Systems Research Institute, San Francisco, CA;